Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.

Ondansetron can cause serious allergic reactions, so use it carefully.

The treatment was effective and tolerable for advanced gastric cancer.

Pulsed electric field treatment may help shrink untreated liver tumors.

Aminopterin was somewhat effective in acute lymphoblastic leukemia in children but did not increase survival time.

Perhexiline can effectively target ovarian cancer cells left after treatment.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Introducing the OTC gene improved symptoms in mice with OTC deficiency.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.

Apraglutide and N-acetylcysteine (NAC) show promise in reducing cytarabine's harmful effects on organs.

Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.

The nano-carrier makes etoposide safer and more effective against lung cancer.

The treatment is safe and shows promise for metastatic breast cancer.

Enhancing immune response can improve cancer treatment effectiveness.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Rituximab leads to longer remission and fewer side effects than cyclophosphamide.

The microreactor effectively fights antibiotic-resistant infections and promotes tissue healing.

Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.

Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Skin problems from transplant drugs are common and need careful management in organ transplant patients.